Abdalla A. Ammar

Abdalla A. Ammar

Auto-generated profile, based on publicly available information

Abdalla A. Ammar

Department of Pharmacy, Yale New Haven Health System, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2021 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
AAAbdalla A. Ammar
Abdalla A. Ammar
MAMahmoud A. Ammar
Mahmoud A. Ammar
KOKent A. Owusu
Kent A. Owusu
SBStacy C. Brown
Stacy C. Brown
FKFiras Kaddouh
Firas Kaddouh
GFGuido J. Falcone
Guido J. Falcone

22 August 2020 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
MAMahmoud A. Ammar
Mahmoud A. Ammar
AAAbdalla A. Ammar
Abdalla A. Ammar
JRJordan Rosen
Jordan Rosen
HKHagar S. Kassab
Hagar S. Kassab
RBRobert D. Becher
Robert D. Becher
Background: Benzodiazepine is first-line therapy for alcohol withdrawal syndrome (AWS), and phenobarbital is an alternative therapy. However, its use has not been well validated in the surgical-trauma patient population. Objective: To describe the use of fixed-dose phenobarbital monotherapy for the management of patients at risk for AWS in the surgical-trauma intensive care unit. Methods: Surgical-trauma critically ill patients who received phenobarbital monotherapy, loading dose followed by a taper regimen, for the management of AWS were included in this evaluation. The effectiveness of phenobarbital monotherapy to treat AWS and prevent development of AWS-related complications were evaluated. Safety end points assessed included significant hypotension, bradycardia, respiratory depression, and need for invasive mechanical ventilation. Results: A total of 31 patients received phenobarbital monotherapy; the majority of patients were at moderate risk for developing AWS (n = 20; 65%) versus high risk (n = 11; 35%). None of the patients developed AWS-related complications; all patients were successfully managed for their AWS. Nine patients (29%) received nonbenzodiazepine adjunct therapy for agitation post–phenobarbital initiation. Three patients (10%) experienced hypotension, and 3 (10%) were intubated. None of the patients had clinically significant bradycardia or respiratory depression. Conclusion and Relevance: Fixed-dose phenobarbital monotherapy appears to be well tolerated and effective in the management of AWS. Further evaluation is needed to determine the extent of benefit with the use of phenobarbital monotherapy for management of AWS.

28 February 2025 in Acute and Critical Care
Verified
Journal Article
Open access
PDF file
CHChristopher Hong
Christopher Hong
MEMuhammad K. Effendi
Muhammad K. Effendi
AAAbdalla A. Ammar
Abdalla A. Ammar
KOKent A. Owusu
Kent A. Owusu
MAMahmoud A. Ammar
Mahmoud A. Ammar
MLMark L. Landreneau
Mark L. Landreneau
Hypotension secondary to autonomic dysfunction is a common complication of acute spinal cord injury (SCI) that may worsen neurologic outcomes. Midodrine, an enteral α-1 agonist, is often used to facilitate weaning intravenous (IV) vasopressors, but its use can be limited by reflex bradycardia. Alternative enteral agents to facilitate this wean in the acute post-SCI setting have not been described. We aim to describe novel application of droxidopa, an enteral precursor of norepinephrine that is approved to treat neurogenic orthostatic hypotension, in the acute post-SCI setting. Droxidopa may be an alternative enteral therapy for those intolerant of midodrine due to reflex bradycardia. We describe two patients suffering traumatic cervical SCI who were successfully weaned off IV vasopressors with droxidopa after failing with midodrine. The first patient was a 64-year-old male who underwent C3–6 laminectomies and fusion after a ten-foot fall resulting in quadriparesis. Post-operatively, the addition of midodrine in an attempt to wean off IV vasopressors resulted in significant reflexive bradycardia. Treatment with droxidopa facilitated rapidly weaning IV vasopressors and transfer to a lower level of care within 72 hours of treatment initiation. The second patient was a 73-year-old male who underwent C3–5 laminectomies and fusion for a traumatic hyperflexion injury causing paraplegia. The addition of midodrine resulted in severe bradycardia, prompting consideration of pacemaker placement. However, with the addition of droxidopa, this was avoided, and the patient was weaned off IV vasopressors on dual oral therapy with midodrine and droxidopa. Droxidopa may be a viable enteral therapy to treat hypotension in patients after acute SCI who are otherwise not tolerating midodrine in order to wean off IV vasopressors. This strategy may avoid pacemaker placement and facilitate shorter stays in the intensive care unit, particularly for patients who are stable but require continued intensive care unit admission for IV vasopressors, which can be cost ineffective and human resource depleting.

23 November 2020 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
AAAbdalla A Ammar
Abdalla A Ammar
MAMahmoud A Ammar
Mahmoud A Ammar
KOKent Owusu
Kent Owusu
EGEmily J Gilmore
Emily J Gilmore
Diagnosis and management of status epilepticus (SE), including non-convulsive status epilepticus (NCSE), is challenging, with a reported 30%–50% of epilepticus patients not responding to available antiseizure medications (ASMs). Injectable benzodiazepines, fosphenytoin, valproate, levetiracetam, lacosamide and phenobarbital are commonly used for treating SE. Brivaracetam, a new ASM, with higher affinity and greater selectivity for the synaptic vesicle glycoprotein 2A than levetiracetam, has been approved as monotherapy or adjunct for treatment of focal onset seizures. Brivaracetam may have a role in the management of SE. However, limited data exist on brivaracetam’s efficacy in SE. We describe a patient case with focal NCSE refractory to levetiracetam, fosphenytoin, lacosamide and valproate who demonstrated clinical and electrographic improvement on continuous electroencephalography monitoring after brivaracetam administration.

14 December 2023 in Critical Care Medicine
Verified
Journal Article
Open access
MAMahmoud Ammar
Mahmoud Ammar
AAAbdalla Ammar
Abdalla Ammar
KOKent Owusu
Kent Owusu
JSJonathan Siner
Jonathan Siner
ACAdam Chess
Adam Chess
JJJennifer Johnson
Jennifer Johnson